University Medical Center Groningen clinical trial pipeline

6 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 3 with minor changes only.

1. Notable

   ASPIRE-1 · DApagliflozin SC0062 and Prevention of Renal Injury…ASPIRE-1 · DApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

   Primary completion pushed from Dec 2027 to Jan 2029

   Also in this update: Study completion pushed from Dec 2028 to Jan 2030

   University Medical Center Groningen·Phase 2· NCT06072326· Registry history of NCT06072326 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

2. Notable

   HOVON161 · Point-of-care Produced CAR T-cell With Commercial…HOVON161 · Point-of-care Produced CAR T-cell With Commercial CAR T-cells · R/R LBCL

   Primary completion pushed from Dec 2025 to Jun 2027

   Also in this update: Enrollment closed, study ongoing; Final enrollment: 340 participants (planned 300)

   University Medical Center Groningen·Phase 2· NCT05641428· Registry history of NCT05641428 on ClinicalTrials.gov (opens the registry)

   Oct 5, 2026

3. Notable

   EHRA-PATHS · Health Economic Evaluation of New Care Pathways

   Primary completion date changed from estimate of Jan 1, 2026 to Jul 1, 2026

   Also in this update: Trial completed; Final enrollment: 703 participants (planned 1300)

   University Medical Center Groningen·Not applicable· NCT05773768· Registry history of NCT05773768 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.